{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:40:44Z","timestamp":1777948844570,"version":"3.51.4"},"reference-count":37,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2025-0033_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Malignant pleural effusion is a common evolution of various cancers and is associated with poor prognosis and quality of life. Currently, the surgical approach is mainly palliative, involving videothoracoscopic talc pleurodesis or the insertion of indwelling pleural catheters. No surgical options with a curative intent are validated for this indication. The aim of our study was to evaluate a score for assessing resectability in pleural carcinomatosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0033_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>122 consecutive patients with recurrent symptomatic pleural effusion, referred to our thoracic surgery department for a surgical exploration of the pleura, were prospectively included. Each patient underwent a detailed description of videothoracoscopic findings, which were summarized in our pleural carcinomatosis score. Resectability was then discussed in our surgical staff meeting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0033_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty patients (65.6\u202f%) were diagnosed with metastatic pleural spread, while 42 patients were diagnosed with benign pleural disease (34.4\u202f%). Patients diagnosed with benign pleural effusion had a median score of 2, and 29 patients (69\u202f%) were considered resectable. Patients diagnosed with malignant pleural effusion had a median score of 11, and only 13 patients (16.2\u202f%) were considered resectable. Those deemed resectable had a median score of 5. The threshold for resectability in our score was set at\u00a06.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0033_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The meticulous exploration of the pleura and calculation of the pleural carcinomatosis score could aid in selecting patients for curative-intent surgery. Patients with a score equal to or less than 6 should be discussed in a multidisciplinary tumor board where the possibility of surgery is considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2025-0033","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:56:34Z","timestamp":1765817794000},"page":"19-25","source":"Crossref","is-referenced-by-count":0,"title":["The utility of a pleural carcinomatosis score for assessing resectability"],"prefix":"10.1515","volume":"11","author":[{"given":"Gabrielle","family":"Drevet","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery , Lung and Heart-Lung Transplantation, H\u00f4pital Louis Pradel, Hospices Civils de Lyon , Lyon , France"},{"name":"EA 3738 CICLY, Universit\u00e9 Claude Bernard Lyon 1 , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaniss","family":"Belaroussi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery , Lung and Heart-Lung Transplantation, H\u00f4pital Louis Pradel, Hospices Civils de Lyon , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Soldea","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery , Lung and Heart-Lung Transplantation, H\u00f4pital Louis Pradel, Hospices Civils de Lyon , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Kovacs","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery , Lung and Heart-Lung Transplantation, H\u00f4pital Louis Pradel, Hospices Civils de Lyon , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Grima","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery , Lung and Heart-Lung Transplantation, H\u00f4pital Louis Pradel, Hospices Civils de Lyon , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Maury","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery , Lung and Heart-Lung Transplantation, H\u00f4pital Louis Pradel, Hospices Civils de Lyon , Lyon , France"},{"name":"EA 3738 CICLY, Universit\u00e9 Claude Bernard Lyon 1 , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Tronc","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery , Lung and Heart-Lung Transplantation, H\u00f4pital Louis Pradel, Hospices Civils de Lyon , Lyon , France"},{"name":"EA 3738 CICLY, Universit\u00e9 Claude Bernard Lyon 1 , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2026050315471966396_j_pp-2025-0033_ref_001","doi-asserted-by":"crossref","unstructured":"Du Rand, I, Maskell, N. Introduction and methods: british thoracic society pleural disease guideline 2010. Thorax 2010;65:ii1\u20133. https:\/\/doi.org\/10.1136\/thx.2010.137042.","DOI":"10.1136\/thx.2010.137042"},{"key":"2026050315471966396_j_pp-2025-0033_ref_002","doi-asserted-by":"crossref","unstructured":"Arnold, DT, De Fonseka, D, Perry, S, Morley, A, Harvey, JE, Medford, A, et al.. Investigating unilateral pleural effusions: the role of cytology. Eur Respir J 2018;52:1801254. https:\/\/doi.org\/10.1183\/13993003.01254-2018.","DOI":"10.1183\/13993003.01254-2018"},{"key":"2026050315471966396_j_pp-2025-0033_ref_003","doi-asserted-by":"crossref","unstructured":"Roberts, ME, Neville, E, Berrisford, RG, Antunes, G, Ali, NJ, BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: british thoracic society pleural disease guideline 2010. Thorax 2010;65:ii32\u201340. https:\/\/doi.org\/10.1136\/thx.2010.136994.","DOI":"10.1136\/thx.2010.136994"},{"key":"2026050315471966396_j_pp-2025-0033_ref_004","doi-asserted-by":"crossref","unstructured":"Antony, VB, Loddenkemper, R, Astoul, P, Boutin, C, Goldstraw, P, Hott, J, et al.. Management of malignant pleural effusions. Eur Respir J 2001;18:402\u201319. https:\/\/doi.org\/10.1183\/09031936.01.00225601.","DOI":"10.1183\/09031936.01.00225601"},{"key":"2026050315471966396_j_pp-2025-0033_ref_005","doi-asserted-by":"crossref","unstructured":"Psallidas, I, Kalomenidis, I, Porcel, JM, Robinson, BW, Stathopoulos, GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev 2016;25:189\u201398. https:\/\/doi.org\/10.1183\/16000617.0019-2016.","DOI":"10.1183\/16000617.0019-2016"},{"key":"2026050315471966396_j_pp-2025-0033_ref_006","doi-asserted-by":"crossref","unstructured":"Bibby, AC, Dorn, P, Psallidas, I, Porcel, JM, Janssen, J, Froudarakis, M, et al.. ERS\/EACTS statement on the management of malignant pleural effusions. Eur Respir J 2018;52:1800349. https:\/\/doi.org\/10.1183\/13993003.00349-2018.","DOI":"10.1183\/13993003.00349-2018"},{"key":"2026050315471966396_j_pp-2025-0033_ref_007","doi-asserted-by":"crossref","unstructured":"Harmon, RL, Sugarbaker, PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005;2:3. https:\/\/doi.org\/10.1186\/1477-7800-2-3.","DOI":"10.1186\/1477-7800-2-3"},{"key":"2026050315471966396_j_pp-2025-0033_ref_008","doi-asserted-by":"crossref","unstructured":"Campany, ME, Reck Dos Santos, PA, Donato, BB, Alwardt, CM, Ernani, V, D\u2019Cunha, J, et al.. Hyperthermic intrapleural chemotherapy: an update. J\u00a0Thorac Dis 2023;15:5064\u201373. https:\/\/doi.org\/10.21037\/jtd-23-454.","DOI":"10.21037\/jtd-23-454"},{"key":"2026050315471966396_j_pp-2025-0033_ref_009","doi-asserted-by":"crossref","unstructured":"Grendelmeier, P, Rahman, NM. What\u2019s the score? Do pleural effusion clinical scoring systems help in management of disease? Semin Respir Crit Care Med 2019;40:394\u2013401. https:\/\/doi.org\/10.1055\/s-0039-1695058.","DOI":"10.1055\/s-0039-1695058"},{"key":"2026050315471966396_j_pp-2025-0033_ref_014","doi-asserted-by":"crossref","unstructured":"Verwaal, VJ, van Ruth, S, de Bree, E, van Sloothen, GW, van Tinteren, H, Boot, H, et al.. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J\u00a0Clin Oncol 2003;21:3737\u201343. https:\/\/doi.org\/10.1200\/jco.2003.04.187.","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2026050315471966396_j_pp-2025-0033_ref_010","doi-asserted-by":"crossref","unstructured":"Heffner, JE, Nietert, PJ, Barbieri, C. Pleural fluid pH\u00a0as a predictor of survival for patients with malignant pleural effusions. Chest 2000;117:79\u201386. https:\/\/doi.org\/10.1378\/chest.117.1.79.","DOI":"10.1378\/chest.117.1.79"},{"key":"2026050315471966396_j_pp-2025-0033_ref_011","doi-asserted-by":"crossref","unstructured":"American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987\u20132001. https:\/\/doi.org\/10.1164\/ajrccm.162.5.ats8-00.","DOI":"10.1164\/ajrccm.162.5.ats8-00"},{"key":"2026050315471966396_j_pp-2025-0033_ref_012","doi-asserted-by":"crossref","unstructured":"Feller-Kopman, DJ, Reddy, CB, DeCamp, MM, Diekemper, RL, Gould, MK, Henry, T, et al.. Management of malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline. Am J Respir Crit Care Med 2018;198:839\u201349. https:\/\/doi.org\/10.1164\/rccm.201807-1415st.","DOI":"10.1164\/rccm.201807-1415ST"},{"key":"2026050315471966396_j_pp-2025-0033_ref_013","doi-asserted-by":"crossref","unstructured":"Walker, S, Mercer, R, Maskell, N, Rahman, NM. Malignant pleural effusion management: keeping the flood gates shut. Lancet Respir Med 2020;8:609\u201318. https:\/\/doi.org\/10.1016\/s2213-2600(19)30373-x.","DOI":"10.1016\/S2213-2600(19)30373-X"},{"key":"2026050315471966396_j_pp-2025-0033_ref_015","doi-asserted-by":"crossref","unstructured":"Alyami, M, H\u00fcbner, M, Grass, F, Bakrin, N, Villeneuve, L, Laplace, N, et al.. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 2019;20:e368\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(19)30318-3.","DOI":"10.1016\/S1470-2045(19)30318-3"},{"key":"2026050315471966396_j_pp-2025-0033_ref_016","doi-asserted-by":"crossref","unstructured":"de Bree, E, van Ruth, S, Baas, P, Rutgers, EJT, van Zandwijk, N, Witkamp, AJ, et al.. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002;121:480\u20137. https:\/\/doi.org\/10.1378\/chest.121.2.480.","DOI":"10.1378\/chest.121.2.480"},{"key":"2026050315471966396_j_pp-2025-0033_ref_017","doi-asserted-by":"crossref","unstructured":"Maury, JM, Girard, N, Tabutin, M, Grima, R, Chalabreysse, L, Pavlakovic, I, et al.. Intra-thoracic chemo-hyperthermia for pleural recurrence of thymoma. Lung Cancer 2017;108:1\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2017.02.014.","DOI":"10.1016\/j.lungcan.2017.02.014"},{"key":"2026050315471966396_j_pp-2025-0033_ref_018","doi-asserted-by":"crossref","unstructured":"Ambrogi, MC, Korasidis, S, Lucchi, M, Fanucchi, O, Giarratana, S, Melfi, F, et al.. Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy. Eur J Cardio Thorac Surg 2016;49:321\u20136. https:\/\/doi.org\/10.1093\/ejcts\/ezv039.","DOI":"10.1093\/ejcts\/ezv039"},{"key":"2026050315471966396_j_pp-2025-0033_ref_019","doi-asserted-by":"crossref","unstructured":"Migliore, M, Nardini, M. Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0-N1 nonsmall cell lung cancer and malignant pleural effusion? Eur Respir Rev 2019;28:190018. https:\/\/doi.org\/10.1183\/16000617.0018-2019.","DOI":"10.1183\/16000617.0018-2019"},{"key":"2026050315471966396_j_pp-2025-0033_ref_020","doi-asserted-by":"crossref","unstructured":"Matsuzaki, Y, Shibata, K, Yoshioka, M, Inoue, M, Sekiya, R, Onitsuka, T, et al.. Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion. Ann Thorac Surg 1995;59:127\u201331. https:\/\/doi.org\/10.1016\/0003-4975(94)00614-d.","DOI":"10.1016\/0003-4975(94)00614-D"},{"key":"2026050315471966396_j_pp-2025-0033_ref_021","unstructured":"Stojiljkovic, D, Nikolic, S, Cvetkovic, A, Jokic, V, Spurnic, I, Jokic, S, et al.. Hyperthermic intrathoracic chemotherapy (HITHOC) in ovarian carcinoma - a propos of a case. J\u00a0BUON 2018;23:153\u20135."},{"key":"2026050315471966396_j_pp-2025-0033_ref_022","doi-asserted-by":"crossref","unstructured":"Jun, SY, Seok, YK, Kato, T, Chun, DS, Lee, YH, Chong, GO, et al.. Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis. Obstet Gynecol Sci 2017;60:308\u201313. https:\/\/doi.org\/10.5468\/ogs.2017.60.3.308.","DOI":"10.5468\/ogs.2017.60.3.308"},{"key":"2026050315471966396_j_pp-2025-0033_ref_023","doi-asserted-by":"crossref","unstructured":"Singh, S, Armstrong, A, Robke, J, Waggoner, S, Debernardo, R. Hyperthermic intra-thoracic chemotherapy (HITeC) for the management of recurrent ovarian cancer involving the pleural cavity. Gynecol Oncol Case Rep 2014;9:24\u20135. https:\/\/doi.org\/10.1016\/j.gynor.2014.05.001.","DOI":"10.1016\/j.gynor.2014.05.001"},{"key":"2026050315471966396_j_pp-2025-0033_ref_024","doi-asserted-by":"crossref","unstructured":"Lombardi, G, Nicoletto, MO, Gusella, M, Fiduccia, P, Dalla Palma, M, Zuin, A, et al.. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer Chemother Pharmacol 2012;69:781\u20137. https:\/\/doi.org\/10.1007\/s00280-011-1765-y.","DOI":"10.1007\/s00280-011-1765-y"},{"key":"2026050315471966396_j_pp-2025-0033_ref_025","doi-asserted-by":"crossref","unstructured":"Zhou, H, Wu, W, Tang, X, Zhou, J, Shen, Y. Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: a systematic review and meta-analysis. Medicine (Baltim) 2017;96. https:\/\/doi.org\/10.1097\/md.0000000000005532.","DOI":"10.1097\/MD.0000000000005532"},{"key":"2026050315471966396_j_pp-2025-0033_ref_026","doi-asserted-by":"crossref","unstructured":"Jonscher, N, Hummels, M, Giger-Pabst, U, Karljalainen, E, Zieren, J, B\u00fcchner, N, et al.. Pressurized IntraThoracic aerosol chemotherapy (PITAC). In: Reymond, MNA, Solass, W, editors. Pressurized IntraPeritoneal aerosol chemotherapy (PIPAC): cancer under pressure. Berlin Boston: De Gruyter; 2014:183\u20136 pp.","DOI":"10.1515\/9783110366617.183"},{"key":"2026050315471966396_j_pp-2025-0033_ref_027","doi-asserted-by":"crossref","unstructured":"Drevet, G, Maury, JM, Bakrin, N, Tronc, F. Technique of pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural effusion. Pleura Peritoneum 2020;5:20200129. https:\/\/doi.org\/10.1515\/pp-2020-0129.","DOI":"10.1515\/pp-2020-0129"},{"key":"2026050315471966396_j_pp-2025-0033_ref_028","doi-asserted-by":"crossref","unstructured":"Giger-Pabst, U, Demtr\u00f6der, C, Falkenstein, TA, Ouaissi, M, G\u00f6tze, TO, Rezniczek, GA, et al.. Pressurized IntraPeritoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer 2018;18:442. https:\/\/doi.org\/10.1186\/s12885-018-4363-0.","DOI":"10.1186\/s12885-018-4363-0"},{"key":"2026050315471966396_j_pp-2025-0033_ref_029","doi-asserted-by":"crossref","unstructured":"Robella, M, Vaira, M, Borsano, A, Mossetti, C, DE Simone, M. Low-dose pressurized intrathoracic aerosol chemotherapy (PITAC) as an alternative therapy for pleuropulmonary involvement in pseudomyxoma peritonei. Anticancer Res 2018;38:929\u201332. https:\/\/doi.org\/10.21873\/anticanres.12305.","DOI":"10.21873\/anticanres.12305"},{"key":"2026050315471966396_j_pp-2025-0033_ref_030","doi-asserted-by":"crossref","unstructured":"Kuchen, N, Cereser, T, Hailemariam, S, Schoeb, O. Safety and efficacy of pressurized intraperitoneal\/intrathoracic aerosol chemotherapy (PIPAC\/PITAC) in patients with peritoneal and\/or pleural carcinomatosis: a preliminary experience. J\u00a0Med Therap 2018;2:1\u20136. https:\/\/doi.org\/10.15761\/jmt.1000127.","DOI":"10.15761\/JMT.1000127"},{"key":"2026050315471966396_j_pp-2025-0033_ref_031","doi-asserted-by":"crossref","unstructured":"Sanchez-Armengol, A, Rodriguez-Panadero, F. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases. Chest 1993;104:1482\u20135. https:\/\/doi.org\/10.1378\/chest.104.5.1482.","DOI":"10.1378\/chest.104.5.1482"},{"key":"2026050315471966396_j_pp-2025-0033_ref_032","doi-asserted-by":"crossref","unstructured":"Sakr, L, Maldonado, F, Greillier, L, Dutau, H, Loundou, A, Astoul, P, et al.. Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implications. J\u00a0Thorac Oncol 2011;6:592\u20137. https:\/\/doi.org\/10.1097\/jto.0b013e318208c7c1.","DOI":"10.1097\/JTO.0b013e318208c7c1"},{"key":"2026050315471966396_j_pp-2025-0033_ref_033","doi-asserted-by":"crossref","unstructured":"Burrows, CM, Mathews, WC, Colt, HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000;117:73\u20138. https:\/\/doi.org\/10.1378\/chest.117.1.73.","DOI":"10.1378\/chest.117.1.73"},{"key":"2026050315471966396_j_pp-2025-0033_ref_034","doi-asserted-by":"crossref","unstructured":"Bielsa, S, Mart\u00edn-Juan, J, Porcel, JM, Rodr\u00edguez-Panadero, F. Diagnostic and prognostic implications of pleural adhesions in malignant effusions. J\u00a0Thorac Oncol 2008;3:1251\u20136. https:\/\/doi.org\/10.1097\/JTO.0b013e318189f53d.","DOI":"10.1097\/JTO.0b013e318189f53d"},{"key":"2026050315471966396_j_pp-2025-0033_ref_035","doi-asserted-by":"crossref","unstructured":"Clive, AO, Kahan, BC, Hooper, CE, Bhatnagar, R, Morley, AJ, Zahan-Evans, N, et al.. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014;69:1098\u2013104. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205285.","DOI":"10.1136\/thoraxjnl-2014-205285"},{"key":"2026050315471966396_j_pp-2025-0033_ref_036","doi-asserted-by":"crossref","unstructured":"Psallidas, I, Kanellakis, NI, Gerry, S, Th\u00e9z\u00e9nas, ML, Charles, PD, Samsonova, A, et al.. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol 2018;19:930\u20139. https:\/\/doi.org\/10.1016\/s1470-2045(18)30294-8.","DOI":"10.1016\/S1470-2045(18)30294-8"},{"key":"2026050315471966396_j_pp-2025-0033_ref_037","doi-asserted-by":"crossref","unstructured":"Bhatt, A, Rousset, P, Benzerdjeb, N, Kammar, P, Mehta, S, Parikh, L, et al.. Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: implications for the preoperative estimation of the peritoneal cancer index. Colorectal Dis 2020;22:2123\u201332. https:\/\/doi.org\/10.1111\/codi.15368.","DOI":"10.1111\/codi.15368"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0033\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0033\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:59:31Z","timestamp":1777841971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0033\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,16]]},"published-print":{"date-parts":[[2026,3,19]]}},"alternative-id":["10.1515\/pp-2025-0033"],"URL":"https:\/\/doi.org\/10.1515\/pp-2025-0033","relation":{},"ISSN":["2364-7671","2364-768X"],"issn-type":[{"value":"2364-7671","type":"print"},{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}